[go: up one dir, main page]

MX2022007120A - Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso. - Google Patents

Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.

Info

Publication number
MX2022007120A
MX2022007120A MX2022007120A MX2022007120A MX2022007120A MX 2022007120 A MX2022007120 A MX 2022007120A MX 2022007120 A MX2022007120 A MX 2022007120A MX 2022007120 A MX2022007120 A MX 2022007120A MX 2022007120 A MX2022007120 A MX 2022007120A
Authority
MX
Mexico
Prior art keywords
binding proteins
binding
nucleic acids
generation
relates
Prior art date
Application number
MX2022007120A
Other languages
English (en)
Inventor
Victor Levitsky
Marcel Walser
Natalia Venetz
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2022007120A publication Critical patent/MX2022007120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con un método para producir proteínas de unión recombinantes con especificidad de unión para un complejo péptido-MHC (pMHC). La invención también se relaciona con proteínas de unión recombinantes que comprenden uno, dos o más dominios de repetición diseñados, preferentemente dominio(s) de repetición de anquirina diseñado(s), con especificidad de unión para un complejo pMHC, y con tales proteínas de unión que comprenden además un agente de unión que tiene especificidad de unión para una proteína expresada en la superficie de una célula inmunitaria, preferentemente una célula T. Además, la invención se relaciona con ácidos nucleicos que codifican tales proteínas de unión o dominios de repetición, composiciones farmacéuticas que comprenden tales proteínas de unión o ácidos nucleicos, y con el uso de tales proteínas de unión, ácidos nucleicos o composiciones farmacéuticas en métodos para tratar o diagnosticar enfermedades, que incluyen cáncer, enfermedades infecciosas y enfermedades autoinmunes.
MX2022007120A 2019-12-11 2020-12-11 Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso. MX2022007120A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19215436 2019-12-11
EP19215435 2019-12-11
EP19215433 2019-12-11
EP19215434 2019-12-11
EP20161059 2020-03-04
EP20181234 2020-06-19
PCT/EP2020/085863 WO2021116469A2 (en) 2019-12-11 2020-12-11 Recombinant peptide-mhc complex binding proteins and their generation and use

Publications (1)

Publication Number Publication Date
MX2022007120A true MX2022007120A (es) 2022-09-09

Family

ID=73790118

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022007120A MX2022007120A (es) 2019-12-11 2020-12-11 Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.
MX2022007122A MX2022007122A (es) 2019-12-11 2020-12-11 Dominios de repetición de anquirina diseñados con residuos de superficie alterados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022007122A MX2022007122A (es) 2019-12-11 2020-12-11 Dominios de repetición de anquirina diseñados con residuos de superficie alterados.

Country Status (11)

Country Link
US (4) US20220106707A1 (es)
EP (2) EP4073091A1 (es)
JP (2) JP2023506765A (es)
KR (2) KR20220113491A (es)
CN (2) CN115003689A (es)
AU (2) AU2020402581A1 (es)
BR (2) BR112022011456A2 (es)
CA (2) CA3161326A1 (es)
IL (2) IL293698A (es)
MX (2) MX2022007120A (es)
WO (2) WO2021116462A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007120A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.
BR112022022456A2 (pt) 2020-05-06 2023-01-10 Molecular Partners Ag Proteínas de ligação de repetição de anquirina e seus usos
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2023021050A1 (en) * 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) * 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
KR20240122764A (ko) 2021-12-14 2024-08-13 몰리큘라 파트너스 아게 이중 결합 특이성을 갖는 설계된 반복 도메인과 이의 용도
MX2024007473A (es) * 2021-12-14 2024-09-10 Cdr Life Ag Activador del linfocito t dirigido al mhc doble.
AU2023317655A1 (en) 2022-08-01 2025-01-23 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024056758A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2024216244A2 (en) 2023-04-13 2024-10-17 Regenxbio Inc. Targeting aav capsids, methods of manufacturing and using same
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
EP2292246A1 (en) 2004-11-12 2011-03-09 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
ATE448305T1 (de) 2005-07-08 2009-11-15 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
WO2009015842A2 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
CN107011425B (zh) 2008-11-03 2021-01-01 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
CN113278077A (zh) 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
JP2014519808A (ja) * 2011-04-29 2014-08-21 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ４／ｉｌ１３に結合する反復タンパク質及び使用
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
JP2015532306A (ja) 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014191574A1 (en) 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
MX375919B (es) 2014-03-14 2025-03-07 Immunocore Ltd Bibliotecas de tcr.
US20170226158A1 (en) * 2014-08-11 2017-08-10 Medimmune Limited Intracellular antigen binding
WO2016154246A1 (en) 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
NZ735803A (en) 2015-04-02 2021-12-24 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
RU2766119C2 (ru) 2016-06-02 2022-02-08 Иммунокор Лимитед Режим дозирования для гибридного белка gp100-специфичный перенаправляющий tcr-анти-cd3 scfv
AU2017331329B2 (en) 2016-09-22 2020-10-29 Molecular Partners Ag Recombinant binding proteins and their use
WO2019099689A1 (en) * 2017-11-16 2019-05-23 The Regents Of The University Of California Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
CN114222757A (zh) 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
WO2020245173A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
MX2021014649A (es) 2019-06-04 2022-01-06 Molecular Partners Ag Dominio de repetición de anquirina diseñado con estabilidad mejorada.
BR112021024236A2 (pt) 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas multiespecíficas
MX2022007120A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.
CN114945584A (zh) 2019-12-11 2022-08-26 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
BR112022022456A2 (pt) * 2020-05-06 2023-01-10 Molecular Partners Ag Proteínas de ligação de repetição de anquirina e seus usos
EP4149960A1 (en) 2020-05-14 2023-03-22 Molecular Partners AG Recombinant cd40 binding proteins and their use
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins

Also Published As

Publication number Publication date
BR112022011456A2 (pt) 2022-08-23
AU2020402581A1 (en) 2022-06-23
US20220064234A1 (en) 2022-03-03
US11578427B2 (en) 2023-02-14
KR20220113492A (ko) 2022-08-12
JP2023506765A (ja) 2023-02-20
JP2023506757A (ja) 2023-02-20
IL293698A (en) 2022-08-01
MX2022007122A (es) 2022-09-09
EP4073091A1 (en) 2022-10-19
US20230243070A1 (en) 2023-08-03
US20230340698A1 (en) 2023-10-26
CA3161321A1 (en) 2021-06-17
BR112022011177A2 (pt) 2022-09-27
WO2021116462A1 (en) 2021-06-17
IL293704A (en) 2022-08-01
WO2021116469A3 (en) 2021-12-02
KR20220113491A (ko) 2022-08-12
EP4073092A2 (en) 2022-10-19
CA3161326A1 (en) 2021-06-17
CN115003689A (zh) 2022-09-02
AU2020402581A9 (en) 2022-07-14
AU2020399230A1 (en) 2022-06-23
US20220106707A1 (en) 2022-04-07
WO2021116469A2 (en) 2021-06-17
CN114929730A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
MX2022007120A (es) Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso.
WO2021116470A3 (en) Recombinant peptide-mhc complex binding proteins and their generation and use
PH12019500596A1 (en) Recombinant binding proteins and their use
MY185845A (en) Icos binding proteins
MX2019003168A (es) Anticuerpos contra proteina alfa reguladora de se?al y metodos de uso.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
SA517390092B1 (ar) مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
PH12017501583B1 (en) Novel proteins specific for cd137
MY156286A (en) Human il-23 antigen binding proteins
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
MA34004B1 (fr) Protéines de liaison à cd127
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
MX2023001256A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
MX2021014601A (es) Proteinas recombinantes de union a fap y su uso.
MX2019008434A (es) Muteínas de lipocalina con afinidad de unión por lag-3.
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
MX2023011978A (es) Captadores de cd70 novedosos basados en darpin.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака